iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

Dec 3 2009

iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that an overview of iCo-007, entitled "iCo-007 a VEGF "+" Agent for the Potential Treatment of Diabetic Macular Edema and Diabetic Retinopathy" will be presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics ("ISOPT"), a major international ocular conference.

A presentation will be given by Dr. Victor H. Gonzalez, ophthalmologist at the Valley Retina Institute, P.A. in McAllen, Texas. The Valley Retina Institute is one of four U.S. sites conducting iCo's ongoing Phase 1 iCo-007 clinical trial. Dr. Victor H. Gonzalez is an American Board of Ophthalmology certified retinal specialist with expertise in adult and pediatric diseases and surgery of the eye. Dr. Gonzalez received his medical degree from Harvard Medical School. He pursued his ophthalmology training at the Doheny Eye Institute in Los Angeles, California and his retinal training from the Massachusetts Eye and Ear Infirmary, a teaching affiliate of Harvard Medical School. He presently serves as Adjunct Clinical Professor at the University of Texas Health Science Center, San Antonio, where his research focus is on genetic studies of diabetes. A frequent lecturer and instructor, Dr. Gonzalez has been influential in offering educational retinal forums both nationally and internationally. His clinic, Valley Retina Institute, has established a comprehensive retinal fellowship program for training national and international retina specialists.

Dr. Gonzalez is also an investigator participating in the Phase I iCo-007 clinical trial. The primary endpoint of the open label, dose escalating trial is safety, with visual acuity and measures of retinal thickness serving as secondary endpoints.